Novo Nordisk A/S (NYSE:NVO) Shares Acquired by First Affirmative Financial Network

First Affirmative Financial Network increased its holdings in Novo Nordisk A/S (NYSE:NVO) by 5.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,903 shares of the company’s stock after acquiring an additional 259 shares during the quarter. First Affirmative Financial Network’s holdings in Novo Nordisk A/S were worth $340,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Victory Capital Management Inc. increased its holdings in shares of Novo Nordisk A/S by 58.5% in the 4th quarter. Victory Capital Management Inc. now owns 62,897 shares of the company’s stock valued at $5,410,000 after acquiring an additional 23,223 shares during the period. Bryn Mawr Capital Management LLC increased its holdings in shares of Novo Nordisk A/S by 358.8% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company’s stock valued at $3,346,000 after acquiring an additional 30,420 shares during the period. DSM Capital Partners LLC increased its holdings in shares of Novo Nordisk A/S by 16.7% in the 4th quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company’s stock valued at $172,678,000 after acquiring an additional 286,912 shares during the period. Channing Global Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $354,000. Finally, Compagnie Lombard Odier SCmA increased its holdings in shares of Novo Nordisk A/S by 5.0% in the 4th quarter. Compagnie Lombard Odier SCmA now owns 67,745 shares of the company’s stock valued at $5,827,000 after acquiring an additional 3,200 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $74.70 on Friday. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15. The stock has a market cap of $335.22 billion, a PE ratio of 22.71, a price-to-earnings-growth ratio of 0.90 and a beta of 0.66. The firm’s fifty day simple moving average is $65.87 and its 200-day simple moving average is $80.71.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The business had revenue of $11.87 billion for the quarter. Analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Guggenheim cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 17th. BMO Capital Markets reissued a “market perform” rating and issued a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Kepler Capital Markets raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. Stifel Nicolaus cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Finally, Dbs Bank cut shares of Novo Nordisk A/S to a “sell” rating in a research note on Friday, April 25th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Hold” and an average price target of $128.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.